Insights

AI Drug Discovery Leader BenevolentAI is a leader in AI-driven drug discovery, offering innovative solutions that increase success rates and reduce timelines in drug development.

Established Technology Advantage The proprietary Benevolent PlatformTM is a validated and recognized AI drug discovery technology, providing a competitive edge in the industry by covering Target Identification, Chemistry, and Drug Repurposing.

Financially Robust With a substantial revenue range of $50M - 100M, BenevolentAI boasts a financially healthy position, indicating a strong foundation for potential business partnerships or collaborations.

Market Leader Potential In a field where complex diseases still lack treatments, BenevolentAI's focus on serving patients with such conditions positions it as a market leader with substantial growth potential.

Strategic London Headquarters Headquartered in London, BenevolentAI operates in a strategic location, offering opportunities for local partnerships and networking within the vibrant technology and pharmaceutical ecosystem of the city.

Similar companies to BenevolentAI

BenevolentAI Tech Stack

BenevolentAI uses 8 technology products and services including Hotjar, Google Hosted Libraries, MySQL, and more. Explore BenevolentAI's tech stack below.

Hotjar
Analytics
Google Hosted Libraries
Content Delivery Network
MySQL
Database
Qualys
Network Security
Windows Server 2012
Operating Systems
Microsoft Azure
Platform As A Service
TypeScript
Programming Languages
C++
Programming Languages

Media & News

BenevolentAI's Email Address Formats

BenevolentAI uses at least 2 format(s):

BenevolentAI Email Formats	Example	Percentage
First.Last@benevolent.ai	John.Doe@benevolent.ai	95%
First.Middle@benevolent.ai	John.Michael@benevolent.ai	2%
First.Middle.Last@benevolent.ai	John.Michael.Doe@benevolent.ai	2%
First.MiddleLast@benevolent.ai	John.MichaelDoe@benevolent.ai	1%
First.Last@benevolent.com	John.Doe@benevolent.com	75%
First@benevolent.com	John@benevolent.com	21%
FirstLast@benevolent.com	JohnDoe@benevolent.com	4%

Frequently Asked Questions

Where is BenevolentAI's headquarters located?

BenevolentAI's main headquarters is located at Maple Street London, Greater London W1T 5HD GB. The company has employees across 5 continents, including EuropeNorth AmericaAfrica.

What is BenevolentAI's stock symbol?

BenevolentAI is a publicly traded company; the company's stock symbol is BAI.AS.

What is BenevolentAI's official website and social media links?

BenevolentAI's official website is benevolent.com and has social profiles on LinkedIn.

How much revenue does BenevolentAI generate?

As of June 2025, BenevolentAI's annual revenue reached $75M.

What is BenevolentAI's NAICS code?

BenevolentAI's NAICS code is 5112 - Software Publishers.

How many employees does BenevolentAI have currently?

As of June 2025, BenevolentAI has approximately 92 employees across 5 continents, including EuropeNorth AmericaAfrica. Key team members include Chief Executive Officer: B. S.Chief People Officer: A. F.Chief Business Officer (formerly Coo), Co-Founder: I. G.. Explore BenevolentAI's employee directory with LeadIQ.

What industry does BenevolentAI belong to?

BenevolentAI operates in the Software Development industry.

What technology does BenevolentAI use?

BenevolentAI's tech stack includes HotjarGoogle Hosted LibrariesMySQLQualysWindows Server 2012Microsoft AzureTypeScriptC++.

What is BenevolentAI's email format?

BenevolentAI's email format typically follows the pattern of . Find more BenevolentAI email formats with LeadIQ.

When was BenevolentAI founded?

BenevolentAI was founded in 2013.

BenevolentAI

Software DevelopmentGreater London, United Kingdom51-200 Employees

BenevolentAI is a pioneer and leader in applying advanced AI to drug discovery and development. 

In a world where drug development failure rate exceeds 90% and thousands of complex diseases lack treatment, our technology can increase the probability of success and reduce timelines. 

Our proprietary Benevolent PlatformTM is one of the industry's most established and validated AI drug discovery technologies. Expertise across Target Identification, Chemistry and Drug Repurposing enables us to deliver across the entire R&D lifecycle. We unite science and technology to serve patients with complex diseases – because it matters.

BenevolentAI is headquartered in London, UK.